Dermal Filler Market to surpass USD 12. 94 billion by 2031 from USD 3. 43 billion in 2021 at a CAGR of 13. 4% in the coming years, i. e. , 2021-31. . Product Overview Dermal fillers are gel-like injectable substances that can be used to restore or enhance the structural components of the body.

New York, May 17, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Impact of COVID-19 on Dermal Filler Market: Segmented; By Type By End user By Application, And Region – Global Analysis Of Market Size, Share & Trends For 2019–2020 And Forecasts To 2031" - https://www.reportlinker.com/p06272878/?utm_source=GNW These fillers are commonly used in areas of the face such as the cheeks, jaw, mouth, lip, and the area around the eye. They restore dermal volume and smooth out wrinkles and other facial lines to give the person being treated a younger appearance. Market Highlights Global Dermal Filler Market is expected to project a notable CAGR of 13.4% in 2031. The growing demand for facial aesthetics treatments is a major factor driving the expansion of medical facilities offering such products and services. Another driver expected to boost market growth is the growing elderly population, which will increase demand for dermal fillers to look younger. The emergence of a large number of private and public hospitals, as well as clinics specializing in skin care and dermatology, necessitates the use of dermal fillers. The growing number of these medical facilities all over the world is a significant factor that is expected to lead to market advancements. Global Dermal Filler Market: Segments A biodegradable segment to grow with the highest CAGR during 2021-31 Based on type, the global Dermal Filler Market is fragmented into Biodegradable and nonbiodegradable. The Biodegradable Dermal Filler Market is expected to account for the lion’s share of the market. Because of their safety and enhanced effectiveness, injectable fillers are preferred options. Furthermore, the increasing availability of biodegradable fillers will contribute to market growth. With the growing popularity of long-lasting cosmetic treatments, the market for biodegradable fillers is expected to grow in the coming years. Hyaluronic Acid providers segment to grow with the highest CAGR during 2021-31 Global Dermal Filler Market is classified based on category into Calcium Hydroxylapatite, Fats, Hyaluronic Acid, Poly-L lactic Acid, and Others. Because it is the gold standard in dermal fillers, hyaluronic acid is expected to account for the largest Global Dermal Filler Market share. The hyaluronic acid segment is being driven by new product launches, and this is expected to drive the Global Dermal Filler Market trend during the forecast period. Other factors expected to drive the growth of the hyaluronic acid segment include the low risk of allergic reactions, the lack of the need for skin testing, and the relatively milder side effects if any. Lip enhancement segment to grow with the highest CAGR during 2021-31 Based on application, the global Dermal Filler Market is fragmented into Facelift, Facial line correction, Lip enhancement, and Others. Lip enhancement is rapidly gaining popularity, with the market expanding at a rapid pace. Dermal fillers are commonly used for lip augmentation among women to achieve plumper and fuller lips. Furthermore, fillers provide a natural appearance to the lips at a low cost and will thus be widely adopted in the market in the future. Market Dynamics Drivers An increasing number of plastic surgeons and per capita disposable income The rising preference for non-invasive aesthetic procedures, an increasing number of plastic surgeons performing aesthetic procedures, and cost-effective alternatives to cosmetic surgeries are key factors driving the Dermal Filler Market. In addition, rising per capita disposable income fuels the growth of the Global Dermal Filler Market. The rise in dermal filler awareness in both developing and developed countries, as well as the emergence of new products and associated new indications, is propelling the Global Dermal Filler Market revenue. Rising investments in R&D and fewer complications Increased investments in research and development for new dermal fillers by major players are also driving sales in the Global Dermal Filler Market. The growth of the Dermal Filler Market is attributed to factors such as the less painful method of treating various facial skin problems, lower occurrences of complications that occur post-surgery, low level of pain, less scarring, and the requirement of smaller incisions. The Dermal Filler Market does not only include facial skin procedures, but also skin aesthetic treatments for other areas of the body. The growing geriatric population has increased the use of anti-aging treatments for skin rejuvenation and collagen restoration. This is also expected to fuel the demand for the dermal filler market. Restraint Unregistered practitioners and high cost The high cost of these fillers is expected to be a significant factor impeding market growth over the forecast period. Furthermore, the presence of unregistered practitioners is expected to have a significant negative impact on the dermal facial fillers market shortly. The negative impact of such fillers is likely to pose a significant challenge to market growth shortly. Global Dermal Filler Market: Key Players Merz Pharma Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis Sinclair Pharma Galderma Laboratories BioPlus Co., Ltd. Candela Corporation BIOXIS pharmaceuticals Suneva Medical SCULPT Luxury Dermal Fillers Ltd Dr. Korman Laboratories Ltd. Other Prominent Players Global Dermal Filler Market: Regions Global Dermal Filler Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American market’s expansion can be attributed to the rising demand for cosmetic products and the growing demand for minimally invasive facial procedures. Furthermore, the growing clinical trials for innovative skin beauty products are expected to fuel the regional market even further. Among all countries in the region, the United States is expected to make a significant contribution to the region’s market development. Impact of Covid-19 on Dermal Filler Market COVID-19 has hurt the Dermal Filler Market, which can be attributed to significant disruptions in their respective manufacturing and supply-chain operations as a result of various precautionary lockdowns, as well as other restrictions imposed by governing authorities around the world. Furthermore, consumer demand has subsequently decreased as people are now more focused on eliminating non-essential expenses from their respective budgets as the general economic status of most people has been severely impacted by this outbreak. Global Dermal Filler Market is further segmented by region into: North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – the United States and Canada Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC the Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA Global Dermal Filler Market report also contains analysis on: Dermal Filler Market Segments: By Type Biodegradable Non-biodegradable By End-userCalcium HydroxylapatiteFats Hyaluronic Acid Poly-L lactic Acid Others By Application Facelift Facial line correction Lip enhancement Others Dermal Filler Market Dynamics Dermal Filler Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies Involved in the Market Value Chain of the Market Market Drivers and Restraints Dermal Filler Market Report Scope and Segmentation Report Attribute Details Market size value in 2021 USD 3.43 billion The revenue forecast in 2031 USD 12.94 billion Growth Rate CAGR of 13.4% from 2021 to 2031 The base year for estimation 2020 Quantitative units Revenue in USD million and CAGR from 2021 to 2031 Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Segments covered Type, End-user, Application, and Region Regional scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) Key companies profiled Merz Pharma, Sinclair Pharma, Galderma Laboratories, BioPlus Co., Ltd., Candela Corporation, BIOXIS pharmaceuticals, Suneva Medical, SCULPT Luxury Dermal Fillers Ltd, Dr. Korman Laboratories Ltd..and Other Prominent Players Read the full report: https://www.reportlinker.com/p06272878/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

Shares of the artificial intelligence lender Upstart Holdings (NASDAQ: UPST) traded more than 16% lower as of 11:14 a.m. ET today after it received yet another downgrade from Wall Street. Wedbush analyst David Chiaverini maintained his underperform rating on Upstart but lowered his price target from $20 to $15 per share. The lower price target comes just a week after Chiaverini lowered his price target on Upstart from $35 to $20.

An earnings recession is not the biggest threat facing the stock market right now. To show that an earnings recession doesn’t necessarily doom the stock market, consider the S&P 500’s (SPX) quarterly return when its earnings-per-share (EPS) is falling. On average over the past century, according to an analysis conducted by Ned Davis Research, the S&P 500 has performed better when its EPS were lower than a year previously — not higher.

When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett buys or sells shares of a company, Wall Street and investors tend to pay close attention. Since becoming CEO in 1965, he's overseen the creation of more than $680 billion in shareholder value and delivered an average annual return of 20.1% for Berkshire's Class A (BRK.A) shareholders (himself included).

Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.

Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.

Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.

Shares of the e-commerce platform company Shopify (NYSE: SHOP) were plunging today just one day after its share price soared by double digits. Today's drop was caused by ongoing fears about high inflation and upcoming Federal Reserve interest rate hikes. As a result, the tech-heavy Nasdaq Composite had slid 2.5% and Shopify's stock had tumbled 10.8% as of 2:44 p.m. ET.

In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]

The Dow Jones reversed higher while the S&P 500 battled out of bear market territory. Tesla stock dived amid reports about CEO Elon Musk.

These companies produce the only thing that matters.

Yahoo Finance Live anchors discuss second-quarter earnings for Deere.

In early trading Friday, stock markets attempted to make a comeback and at least end a losing week on a winning note. As of 12:25 p.m. ET, shares of Rivian Automotive (NASDAQ: RIVN) are off 4.9%, Nikola (NASDAQ: NKLA) stock is down 5.8%, and Lucid Group (NASDAQ: LCID) -- the beneficiary of positive news as recently as yesterday -- is giving back most of its gains, and leading the sector 6.8% lower today.

In early trading Friday, stock markets attempted to make a comeback and end a down week on an up note. As The Fly reports, Truist has only a neutral rating on each of Royal Caribbean and Norwegian Cruise Line -- and rates Carnival stock an out and out sell.

Investors weren't overjoyed about a fresh debt offering announced by Carnival, and a bearish new note from an analyst didn't help, either. After market hours on Wednesday, Carnival announced that it is floating a private offering of $1 billion worth of senior unsecured notes. Carnival says it plans to use the net proceeds of the issue to make scheduled principal payments on debt during fiscal 2023 and for general corporate purposes.

(Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Stocks Avert Bear

Nio (NYSE: NIO) shares began trading on the main board of the Singapore stock exchange today prior to the opening of the U.S. markets. After initially popping 20% early, the new shares ended up closing in Singapore about 2.4% higher, according to Barron's.

In less than week -- Wednesday, May 25 -- Nvidia (NVDA) is due to report its Q1 2022 earnings. Analysts on average are optimistic about the report itself, and also about the guidance Nvidia might give, predicting Nvidia will report 43% growth to $1.30 per share this quarter, and promise investors another 31% worth of growth ($1.36 per share) next quarter. And one analyst thinks Nvidia could do even better than that. Previewing next Wednesday's earnings report, Oppenheimer's Rick Schafer reiterat

Like many tech and fintech stocks this year, the Berkshire Hathaway-backed Brazilian digital bank Nu Holdings (NYSE: NU) has seen its stock price struggle and is down more than 61% this year. Nu is a major disruptor in the Latin American banking space, first offering a credit card with no annual fees and then building out a suite of banking products from there. Nu has amassed close to 60 million customers but in the past has gotten questions regarding its high valuation and path to sustainable profitability.

Rising interest rates, supply chain constraints and Russia’s invasion of Ukraine are all issues currently plaguing the macro climate. The problem with all three, says Tony Dwyer, Canaccord Chief Market Strategist, is that for each problem there’s “no easy exit strategy.” The tough conditions are likely to persist, then. However, on the plus side, while these issues have sent most corners of the stock market into a tailspin, now investors are presented with stocks for which the term “oversold” re

In this article, we discuss Michael Burry’s short position in Apple Inc. (NASDAQ:AAPL) and the 5 stocks he is selling in 2022. If you want to skip our analysis of Burry’s history, investment philosophy, and hedge fund performance, go directly to Michael Burry Is Selling These 3 Stocks in 2022. Michael Burry was born on […]